tritanrix-hepb
Vaccineexperimental
Clinical trial activity
9 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
9
Phase 3
5
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00228917)
Timeline
Indications
Mechanism of action
- Tetanus toxinImmunity, active
tetX immunity, active
- Hepatitis B virusImmunity, active
Hepatitis B virus immunity, active
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
- Diphtheria toxinImmunity, active
Diphtheria toxin immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- trianrix-hepb
- tritanrix-hepb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01262872 | Phase 2 | Feb 9, 2011 | Department of State for Health and Social Welfare, The Gambia, GlaxoSmithKline, Medical Research Council, The Gambia, PATH, University of London |
| NCT01231503 | Phase 2 | Jan 1, 2011 | GlaxoSmithKline, PATH |
| NCT01098474 | Phase 2 | Jul 1, 2010 | Aeras, GlaxoSmithKline |
| NCT00814710 | Phase 3 | Mar 1, 2009 | GlaxoSmithKline |
| NCT00829010 | Phase 3 | Feb 1, 2009 | GlaxoSmithKline |
| NCT00547248 | Phase 3 | Oct 1, 2007 | GlaxoSmithKline |
| NCT00436007 | Phase 2 | Apr 30, 2007 | GlaxoSmithKline |
| NCT00344318 | Phase 3 | Aug 1, 2006 | GlaxoSmithKline |
| NCT00228917 | Phase 3 | Jun 1, 2005 | GlaxoSmithKline |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 9 | 9 | 2 | 2005 |
| PATH | Academic/Hospital | 2 | 0 | 1 | 2011 |
| Aeras | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Department of State for Health and Social Welfare, The Gambia | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Medical Research Council, The Gambia | Government | 1 | 0 | 1 | 2011 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2011 |
6 organizations
Page 1 / 1